Prof Gaudernack is a pioneer in the development of cancer vaccines and cancer immunotherapy. He has throughout his career developed various strategies in immunological treatment of cancer. He is actively involved in several ongoing cellular and immuno-gene therapeutic clinical trials and his former research group has put major efforts into the development of various T cell-based immunotherapeutic strategies. He was a Professor and Head of Unit for Immunotherapy at the Norwegian Radium Hospital from 1995 to 2011. He initiated over 20 clinical studies in therapeutic cancer vaccination, including the first peptide therapeutic vaccine study in cancer world-wide (mutant RAS). Prof Gaudernack has more than 50 patents and 15 licenses of monoclonal antibodies, therapeutic cancer vaccines and cancer diagnostics.